Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
NAD+ vs. Liraglutide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
NAD+ is distinguished by nAD+ is the oxidized coenzyme itself—not NADH and not the precursors NR, NMN, niacin, or nicotinamide. Most human NAD-boosting evidence belongs to those other molecules; Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
NAD+ is distinguished in the current record by nAD+ is the oxidized coenzyme itself—not NADH and not the precursors NR, NMN, niacin, or nicotinamide. Most human NAD-boosting evidence belongs to those other molecules. Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceLiraglutide
NAD+: Early direct human evidence. Liraglutide: Mature human evidence.
Regulatory historyLiraglutide
NAD+: Not FDA approved for wellness use. Liraglutide: FDA approved for defined product-specific indications.
Mechanistic breadthNAD+
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
NAD+
- Cellular energy and redox metabolism
- Aging and NAD+ decline
- Ischemic-cardiomyopathy heart failure
- IV metabolism and tolerability
Liraglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Adolescent obesity
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
NAD+Not approved for wellness use
No FDA-approved NAD+ injectable or wellness/anti-aging indication was located. FDA also documented 503B bulk-compounding ineligibility and endotoxin-related injectable reactions.
LiraglutideFDA-labeled indications
FDA approved in product-specific daily injection formulations for chronic weight management, type 2 diabetes, and cardiovascular-risk reduction in a defined diabetes population.
Evidence depthEvidence, not a winner
NAD+One RCT; tiny IV pilots
One 180-person disease-specific randomized trial, one 11-person IV metabolism pilot, one 14-person commercial record review containing six NAD+ clients, and broader reviews dominated by NR/NMN studies.
LiraglutideMature Phase 3 + outcomes
Multiple randomized Phase 3 trials and the 9,340-participant LEADER cardiovascular outcomes trial, with adult and pediatric product-specific evidence.
Weight outcomesEvidence, not a winner
NAD+No direct evidence
No controlled direct-NAD+ evidence for weight loss, appetite suppression, or body-composition benefit was located.
LiraglutidePeer-reviewed Phase 3
SCALE reported −8.4 kg mean change at 56 weeks versus −2.8 kg placebo. STEP 8 directly compared liraglutide 3.0 mg with semaglutide 2.4 mg.
Type 2 diabetesEvidence, not a winner
NAD+No direct evidence
No controlled direct-NAD+ evidence for diabetes treatment or glycemic benefit was located. Precursor studies must not be assigned to NAD+ itself.
LiraglutideApproved + pediatric trial
Victoza has extensive adult evidence and controlled pediatric evidence beginning at age 10. Product-specific labeled doses differ from weight-management use.
Obstructive sleep apnoeaEvidence, not a winner
NAD+No direct evidence
No controlled direct-NAD+ evidence for sleep apnea or sleep-quality improvement was located.
LiraglutideControlled study; not approved
A 359-participant trial found a larger reduction in apnea–hypopnea index than placebo, but no U.S. liraglutide OSA indication was identified.
Cardiovascular outcomesEvidence, not a winner
NAD+Early disease-specific signal
One single-center randomized trial reported a short-term LVEF improvement in ischemic-cardiomyopathy heart failure; clinical-event and functional outcomes were nonsignificant trends.
LiraglutideLEADER + labeled use
LEADER found fewer major cardiovascular events in adults with type 2 diabetes and high cardiovascular risk, supporting a defined Victoza indication.
Administration and handlingEvidence, not a winner
NAD+Study protocols only
Published IV studies used different disease-specific or exploratory protocols. No universal approved dose, infusion rate, route, reconstitution, storage, cycle, or combination standard exists.
LiraglutideDaily product-specific injection
Current approved products are once-daily subcutaneous, ready-to-use solutions. Saxenda and Victoza have different labeled dose ranges, purposes, and instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Whether direct NAD+ produces meaningful, durable benefits outside that narrow cardiac setting and what formulation-specific safety looks like.
- Long-term comparative outcomes versus newer weekly incretin therapies and whether narrower research findings become approved uses.
Community Intelligence
Emerging patterns, clearly separated from evidence
NAD+
No community experiences yetBe the first account holder to contribute.
Liraglutide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.